EUVIMEDEUVIMED entdecken
Crossref

Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor

Dong-Ming Shen iD, Kate F Byth, Damien Bertheloot, Simona Braams, Sarah Bradley, Dennis Dean, Carien Dekker, Ayman F El-Kattan, Luigi Franchi, Gary D Glick, Shomir Ghosh, Alexandra Hinniger und 13 weitere

Journal of Medicinal Chemistry · 13.03.2025 · 68 (5) · 5529-5550

DOI: 10.1021/acs.jmedchem.4c02759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.03.2025. Verfasst von Dong-Ming Shen und 24 weiteren Autor:innen. Beteiligte Einrichtung: IFM Therapeutics, Boston, Massachusetts 02116, United States. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 113 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of DFV890 ((R)-1), a potent and selective NLRP3 antagonist, is described. Replacement of the sulfonyl urea core from the first-generation NLRP3 antagonist CRID3 with a sulfonimidamide core afforded a novel and potent series of NLRP3 antagonists. The (R)-enantiomers of the sulfonimidamide series were found to be consistently more potent than structurally related sulfonyl ureas. Replacement of the furan unit of CRID3 with a 5-substituted thiazole unit led to DFV890 ((R)-1), which potently inhibited IL-1β production in THP-1 cells and in primary human cells, blocked multiple downstream effectors of NLRP3 activation, and substantially improved PK properties and significantly lowered the predicted human dose compared to that for CRID3. DFV890 ((R)-1) was also effective in an air pouch model of gout.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesHumansStructure-Activity RelationshipAnimalsInterleukin-1betaDrug DiscoveryGoutSulfonamidesMiceTHP-1 CellsRatsMale

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesInterleukin-1betaSulfonamidesNLRP3 protein, human

Autor:innen und Institutionen

  • IFM Therapeutics, Boston, Massachusetts 02116, United States.
  • IFM Therapeutics GmbH, Bonn 53127, Germany.
  • Novartis Biomedical Research, Basel CH-4002, Switzerland.
  • IFM Therapeutics, Ann Arbor, Michigan 48108, United States.

ORCID-Profile: Dong-Ming Shen, Jason D Katz, William R Roush

Zitieren

APA

Shen, D. M., Byth, K. F., Bertheloot, D., Braams, S., Bradley, S., Dean, D., Dekker, C., El-Kattan, A. F., Franchi, L., Glick, G. D., Ghosh, S., Hinniger, A., Katz, J. D., Kitanovic, A., Lu, X., Olhava, E. J., Opipari, A. W., Sanchez, B., Seidel, H. M., …, & Roush, W. R. (2025). Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor. Journal of Medicinal Chemistry, 68(5), 5529-5550. https://doi.org/10.1021/acs.jmedchem.4c02759

Vancouver

Shen DM, Byth KF, Bertheloot D, Braams S, Bradley S, Dean D, et al. Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor. Journal of Medicinal Chemistry. 2025;68(5):5529-5550. doi:10.1021/acs.jmedchem.4c02759

BibTeX
@article{Shen2025,
  author = {Shen, Dong-Ming and Byth, Kate F and Bertheloot, Damien and Braams, Simona and Bradley, Sarah and Dean, Dennis and Dekker, Carien and El-Kattan, Ayman F and Franchi, Luigi and Glick, Gary D and Ghosh, Shomir and Hinniger, Alexandra and Katz, Jason D and Kitanovic, Ana and Lu, Xiaokang and Olhava, Edward J and Opipari, Anthony W and Sanchez, Brian and Seidel, H Martin and Stunden, James and Stutz, Andrea and Telling, Alissa and Venkatraman, Shankar and Winkler, David G and Roush, William R},
  title = {Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {5},
  pages = {5529--5550},
  doi = {10.1021/acs.jmedchem.4c02759}
}
Kostenlos starten →